STA Wealth Management LLC acquired a new position in Sanofi SA (NYSE:SNY) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,372 shares of the company’s stock, valued at approximately $58,996,000. Sanofi makes up about 15.8% of STA Wealth Management LLC’s investment portfolio, making the stock its biggest position.
Several other institutional investors have also bought and sold shares of the company. BNP Paribas Arbitrage SA raised its stake in Sanofi by 8.3% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 15,374 shares of the company’s stock worth $765,000 after acquiring an additional 1,183 shares during the last quarter. Atlantic Trust Group LLC raised its stake in Sanofi by 3.1% in the 3rd quarter. Atlantic Trust Group LLC now owns 42,145 shares of the company’s stock worth $2,099,000 after acquiring an additional 1,275 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its stake in Sanofi by 46.0% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 4,325 shares of the company’s stock worth $186,000 after acquiring an additional 1,362 shares during the last quarter. E&G Advisors LP raised its stake in Sanofi by 6.3% in the 4th quarter. E&G Advisors LP now owns 23,625 shares of the company’s stock worth $1,016,000 after acquiring an additional 1,400 shares during the last quarter. Finally, Rockefeller Financial Services Inc. raised its stake in Sanofi by 8.4% in the 4th quarter. Rockefeller Financial Services Inc. now owns 18,095 shares of the company’s stock worth $778,000 after acquiring an additional 1,409 shares during the last quarter. 8.94% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages recently issued reports on SNY. Deutsche Bank restated a “buy” rating on shares of Sanofi in a research note on Monday. Sanford C. Bernstein restated a “market perform” rating and issued a $45.00 target price (down previously from $50.00) on shares of Sanofi in a research note on Thursday, February 8th. Nord/LB restated a “neutral” rating on shares of Sanofi in a research note on Tuesday, January 2nd. ValuEngine lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research note on Thursday, January 11th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $49.33.
Sanofi (NYSE:SNY) last released its quarterly earnings data on Wednesday, February 7th. The company reported $0.62 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.69 by ($0.07). The company had revenue of $8.69 billion for the quarter, compared to analysts’ expectations of $8.65 billion. Sanofi had a net margin of 23.25% and a return on equity of 24.30%. The business’s quarterly revenue was down 2.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.25 EPS. equities research analysts expect that Sanofi SA will post 3.36 earnings per share for the current fiscal year.
The business also recently disclosed an annual dividend, which will be paid on Monday, June 4th. Shareholders of record on Thursday, May 10th will be paid a dividend of $1.8609 per share. The ex-dividend date is Wednesday, May 9th. This represents a dividend yield of 4.72%. This is a positive change from Sanofi’s previous annual dividend of $1.58. Sanofi’s dividend payout ratio (DPR) is presently 30.14%.
TRADEMARK VIOLATION WARNING: This news story was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/03/14/1372-shares-in-sanofi-sa-sny-purchased-by-sta-wealth-management-llc.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.